N4BP2L1

Across TCGA pan-cancer cohorts, N4BP2L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated N4BP2L1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher N4BP2L1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated N4BP2L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where N4BP2L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.870	0.643	.015	10	view →
LUAD	DFS	Median	III,IV	1.000	0.409	.024	7	view →
GBM	OS	Tertile	All	0.392	0.637	.037	2	view →
UCEC	DFS	Median	All	0.919	1.000	.038	2	view →
HNSC	DFS	Median	II,III,IV	0.911	1.000	.048	1	view →
LSCC	OS	Median	All	0.951	0.832	.012	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

N4BP2L1–CCRCC (OS)

Open the CCRCC breakdown →